Jul. 9 at 10:44 AM
$APVO The clinical data is genuinely strong: mipletamig (frontline AML) posted 87% clinical benefit and 81% remission across 31 evaluable patients through Cohort 5, "substantially outperforming benchmark," with the RAINIER trial on track for 2026 completion. That's a real, positive signal.
The problem is everything else. This is a ~
$6M market-cap microcap running on a
$60M equity line of credit with Yorkville Advisors — a financing structure that by design means continuous share issuance into the market as the company draws it down. TTM diluted EPS of -
$87 tells you there's already been extreme share-count churn (likely reverse splits). There's also a flagged single-day drop of ~38%. Cash runway is extended out to 2029 via the ELOC, so it won't go bankrupt soon, but existing holders should expect continuous dilution pressure regardless of how the trial reads out. Good science, bad vehicle for capital preservation.
